Iovance Biotherapeutics
IOVA
C$2.56
Share price
-3.11%
Change (1 day)
-77.74%
Change (1 year)
Categories
Iovance Biotherapeutics (IOVA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : C$0.27 Billion
According to Iovance Biotherapeutics 's latest financial reports the company's total liabilities are C$0.27 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Iovance Biotherapeutics - Total liabilities on balance sheet (from 2008 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | C$0.28 B | 10.56% |
| 2023-12-31 | C$0.25 B | 16.42% |
| 2022-12-31 | C$0.22 B | 12.4% |
| 2021-12-31 | C$0.19 B | 38.98% |
| 2020-12-31 | C$0.14 B | 139.26% |
| 2019-12-31 | C$59.66 M | 199.43% |
| 2018-12-31 | C$19.92 M | 60.22% |
| 2017-12-31 | C$12.43 M | 86.28% |
| 2016-12-31 | C$6.67 M | 195.26% |
| 2015-12-31 | C$2.26 M | 17.24% |
| 2014-12-31 | C$1.92 M | -20.18% |
| 2013-12-31 | C$2.41 M | -78.59% |
| 2012-12-31 | C$11.28 M | -16.89% |
| 2011-12-31 | C$13.57 M | 1550.86% |
| 2010-12-31 | C$0.82 M | 3281.19% |
| 2009-12-31 | C$0.02 M | 501.18% |
| 2008-12-31 | C$0 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | C$0.14 B | -46.95% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | C$4.3 M | -98.42% | Bahamas |